The pathway to secondary prevention of Alzheimer's disease

Eric McDade, Martin M. Bednar, H. Robert Brashear, David S. Miller, Paul Maruff, Christopher Randolph, Zahinoor Ismail, Maria C. Carrillo, Christopher J. Weber, Lisa J. Bain, Ann Marie Hake

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre-clinical AD. This review will address the biological approach to defining pre-clinical AD, detection, identification of at-risk individuals, and lessons learned from trials such as A4 and TOMMORROW.

Original languageEnglish
Article numbere12069
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Issue number1
StatePublished - 2020


  • Alzheimer's disease
  • biomarkers
  • clinical trials
  • research roundtable


Dive into the research topics of 'The pathway to secondary prevention of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this